Contact Congress about H.R. 2821: FDA Modernization Act 3.0

The FDA would have to update drug testing rules within one year. The rules would replace many references to animal testing with broader language for nonclinical testing before human trials.

Modern Action explains what the legislation does, helps you choose whether to support, oppose, or ask for changes, and drafts a message tied to the bill, your stance, and the elected officials who can act on it.

FDA Modernization Act 3.0 is a Senate bill awaiting final action. The latest recorded action: Received in the Senate.

Latest action on H.R. 2821: Received in the Senate.

Who this affects: This bill mainly affects drug companies, researchers, FDA staff, and groups that track animal use in research. Drug developers would see updated rules on what evidence FDA may accept before human trials. FDA would have to revise its rulebook quickly and may need to update more sections than the bill names. Patients and the public could see effects later, depending on how FDA applies these rules to drug safety reviews.

Why this matters: This bill matters because drug testing rules shape what evidence companies must show before testing drugs in people. Updating the wording could make FDA rules better match newer testing tools and recent law. It may also help companies understand when non-animal methods can support a drug application. The real effect will depend on FDA’s rule and how the agency judges safety evidence in each case.

Key provisions in H.R. 2821

• FDA must issue a fast rule on nonclinical testing within one year after the bill becomes law. This kind of rule is called an interim final rule and can take effect quickly.
• FDA drug rules must stop focusing only on “animal” tests in several places. They must use “nonclinical” tests instead, meaning tests done before human trials.
• FDA must add the legal meaning of “nonclinical test” to several specific rule sections. These are sections 312.3, 314.3, 315.2, and 601.31 of Title 21 of the Code of Federal Regulations, the federal rulebook for FDA.
• FDA may update more rule sections if needed. Those changes must keep FDA rules in line with drug law changes Congress made in the 2023 Consolidated Appropriations Act.
• The new FDA rule would take effect right away. FDA would not have to prove “good cause,” which is the usual legal reason for making a rule effective before the full process ends.

How Modern Action helps you take action on H.R. 2821

You do not have to start with a blank letter. Modern Action turns the bill, your position, and the relevant congressional context into a message you can edit and send. The goal is to make contacting Congress clear, specific, and useful without forcing you to parse bill text or figure out the right office on your own.

Questions people ask about H.R. 2821

What is H.R. 2821?

The FDA would have to update drug testing rules within one year. The rules would replace many references to animal testing with broader language for nonclinical testing before human trials.

How do I support or oppose H.R. 2821?

Choose support, oppose, or ask for changes on Modern Action. The action flow drafts the message for you and keeps the wording tied to this bill.

Who should I contact about H.R. 2821?

Modern Action uses your location to route the action to the congressional offices relevant to the bill and your representation.

How does Modern Action help me act on H.R. 2821?

Modern Action gives you bill-specific context, lets you choose support, opposition, or changes, and drafts a message from your position and reasons.